LOGIN  |  REGISTER
C4 Therapeutics
Terns Pharmaceuticals

908 Devices to Participate in Upcoming Investor Conferences

March 03, 2025 | Last Trade: US$8.99 0.43 5.02

BOSTON / Mar 03, 2025 / Business Wire / 908 Devices Inc. (Nasdaq: MASS), a pioneer of purpose-built handheld and desktop devices for chemical analysis, today announced it will participate in the following investor conferences.

  • TD Cowen 45th Annual Healthcare Conference, Boston, MA
    Fireside chat on Wednesday, March 5 at 9:50 a.m. Eastern Time
  • Leerink Global Healthcare Conference, Miami, FL
    Fireside chat on Tuesday, March 11 at 1 p.m. Eastern Time

Interested parties may access a live and archived webcast of these sessions on the “Investors” section of the company website at: www.908devices.com.

About 908 Devices

908 Devices is revolutionizing chemical analysis with its simple handheld and desktop devices, addressing life-altering applications. The Company’s devices are used at the point-of-need to interrogate unknown and invisible materials and provide quick, actionable answers to directly address some of the most critical problems in forensics, bioprocessing, pharma/biopharma, life sciences research and adjacent markets. The Company is headquartered in the heart of Boston, where it designs and manufactures innovative products that bring together the power of complementary analytical technologies, microfluidic sampling and separations, software automation, and machine learning.

Astria Therapeutics

Stock Quote

Featured Stock

ClearPoint Neuro

ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...

CLICK TO LEARN MORE

Featured Stock

C4 Therapeutics

C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page